ReviewPediatric blood & cancer2013
Children's Oncology Group's 2013 blueprint for research: bone tumors.
Review in Pediatric blood & cancer, 2013. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 120 papers, 2 of them syntheses that pooled it.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
120 citing papers in PubMed, 2 syntheses or guidelines pooled it, 231 citations in OpenAlex.
- Prognostic and clinicopathological value of systemic immune-inflammation index in patients with osteosarcoma: a meta-analysis.Frontiers in immunology · 2024Pooled it
- High-dose chemotherapy followed by autologous haematopoietic cell transplantation for children, adolescents, and young adults with primary metastatic Ewing sarcoma.The Cochrane database of systematic reviews · 2021Pooled it
- Camrelizumab in combination with doxorubicin, cisplatin, ifosfamide, and methotrexate in neoadjuvant treatment of resectable osteosarcoma: A prospective, single-arm, exploratory phase II trial.Cancer medicine · 2024Trial
- Ewing's Sarcoma of the Head and Neck: Margins are not just for surgeons.Cancer medicine · 2018Trial
- Rho GTPase-activating protein 35 rs1052667 polymorphism and osteosarcoma risk and prognosis.BioMed research international · 2014Trial
- Clustered structural variant hotspots enable oncogenic addiction and plasticity in osteosarcoma.bioRxiv : the preprint server for biology · 2026Article
- Pediatric sarcomas: challenges and opportunities.Genes & development · 2026Review
- Safety and Feasibility of Infusing Ex Vivo Expanded Allogeneic Canine Natural Killer Cells for the Treatment of Metastatic Solid Tumours.Veterinary and comparative oncology · 2026Article
- Radiomics-based causal machine learning for exploratory treatment-effect estimation of neoadjuvant chemotherapy cycle intensity in osteosarcoma: a proof-of-concept study.BMC medical imaging · 2026Article
- Safety and Feasibility of InfusingbioRxiv : the preprint server for biology · 2026Article
- Near-Infrared Imaging Using a Cathepsin-Targeted, Quenched Activity-Based Probe Identifies Naturally Occurring Canine Appendicular Osteosarcoma.Clinical cancer research : an official journal of the American Association for Cancer Research · 2026Article
- Single-Cell Transcriptomic Analysis Suggests That JUN May Regulate BAMBI to Promote Osteosarcoma Cell Migration and Invasion.Human mutation · 2026Article
- Etoposide activates CD8Journal for immunotherapy of cancer · 2025Article
- Resveratrol synergizes with cisplatin to suppress osteosarcoma U2-OS cells via up-regulating Cx43 and inducing ROS-dependent apoptosis.Discover oncology · 2025Article
- End-to-End Deep Learning Prediction of Neoadjuvant Chemotherapy Response in Osteosarcoma Patients Using Routine MRI.Journal of imaging informatics in medicine · 2025Article
- Periprosthetic seromas and a third space effect after high-dose methotrexate.Wiener klinische Wochenschrift · 2025Article
- Multiscale metal-based nanocomposites for bone and joint disease therapies.Materials today. Bio · 2025Review
- HEY1 promotes the development and metastasis of osteosarcoma through CD44/EGFR/FAK pathway.Journal of cellular and molecular medicine · 2025Article
- Predicting lung metastasis in high-grade Osteosarcoma: The role of CTA Signs, with a Focus on vascular wrapping and intratumoral vascular network.Journal of bone oncology · 2025Article
- Drug Sensitivity Testing in Osteosarcoma: A Case Report.Current oncology (Toronto, Ont.) · 2025Article
60 more citing papers are in PubMed but not listed here.
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
6 authors at 5 institutions in 1 country.
Funding
Abstract
In the US, approximately 650 children are diagnosed with osteosarcoma and Ewing sarcoma (ES) each year. Five-year survival ranges from 65% to 75% for localized disease and <30% for patients with metastases. Recent findings include interval-compressed five drug chemotherapy improves survival with localized ES. In osteosarcoma a large international trial investigating the addition of ifosfamide/etoposide or interferon to standard therapy has completed accrual. For ES an ongoing trial explores the addition of cyclophosphamide/topotecan to interval-compressed chemotherapy. Trials planned by the Children's Oncology Group will investigate new target(s) including IGF-1R and mTOR in ES, and RANKL and GD2 in osteosarcoma.
Indexed as
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.